1999
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment
Elsworth J, Taylor J, Sladek J, Collier T, Redmond D, Roth R. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 1999, 95: 399-408. PMID: 10658619, DOI: 10.1016/s0306-4522(99)00437-6.Peer-Reviewed Original ResearchConceptsHomovanillic acid/dopamine ratioMPTP treatmentStriatal dopamine levelsDopamine levelsDopamine lossDopamine depletionDopamine ratioStriatal subregionsNucleus accumbensCaudate nucleusDopamine concentrationsOne-yearSeverity categoriesDopamine neuron integrityVentromedial caudate nucleusStriatal dopamine lossHomovanillic acid concentrationsStriatal dopaminergic functionMarked increaseNormal motor performancePaucity of dataMetabolic activityNon-human primatesParkinsonian disabilityTetrahydropyridine (MPTP) model
1997
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
Taylor J, Elsworth J, Roth R, Sladek J, Redmond D. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81: 745-755. PMID: 9316026, DOI: 10.1016/s0306-4522(97)00214-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseSevere parkinsonismAdult male African green monkeysMale African green monkeysTetrahydropyridine-induced parkinsonismMPTP-induced parkinsonismIdiopathic Parkinson's diseaseNovel therapeutic treatmentsLong-term deficitsAfrican green monkeysGroups of animalsNon-human primatesMPTP treatmentParkinsonian monkeysMPTP administrationVervet monkeysFunctional deficitsInitial severityStable parkinsonismBehavioral deficitsAnimal modelsParkinsonismParkinsonian subjectsMPTPTherapeutic treatment